FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

 OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                       
1. Name and Address of Reporting Person * Balthaser Kevin 2. Date of Event Requiring Statement (MM/DD/YYYY)
1/1/2023 

 3. Issuer Name and Ticker or Trading Symbol Aclaris Therapeutics, Inc. [ACRS]
(Last)        (First)        (Middle)
C/O ACLARIS THERAPEUTICS, INC., 640 LEE ROAD, SUITE 200		 4. Relationship of Reporting Person(s) to Issuer (Check all applicable)_____ Director                          _____ 10% Owner
___X___ Officer (give title below)        _____ Other (specify below)
Chief Financial Officer /
(Street)
WAYNE, PA 19087      
(City)              (State)              (Zip)
 5. If Amendment, Date Original Filed(MM/DD/YYYY)
 

 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		 2. Amount of Securities Beneficially Owned
(Instr. 4)		 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		 4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock  700  D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)		 2. Date Exercisable and Expiration Date
(MM/DD/YYYY)		 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		 6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (Right to Buy)   (1) 7/4/2027  Common Stock  11200  $27.54  D   
Employee Stock Option (Right to Buy)   (1) 1/31/2028  Common Stock  2100  $22.09  D   
Employee Stock Option (Right to Buy)   (2) 2/28/2031  Common Stock  15500  $24.06  D   
Employee Stock Option (Right to Buy)   (3) 2/29/2032  Common Stock  33400  $14.94  D   
Restricted Stock Units   (4)  (4) Common Stock  1475   (5) D   
Restricted Stock Units   (6)  (6) Common Stock  3000   (5) D   
Restricted Stock Units   (7)  (7) Common Stock  2000   (5) D   
Restricted Stock Units   (8)  (8) Common Stock  3300   (5) D   
Restricted Stock Units   (9)  (9) Common Stock  9500   (5) D   

Explanation of Responses:
(1)  The shares underlying this option are fully vested. The expiration date of this option reported in the table is the day before the tenth anniversary of the grant date of the option.
(2)  The option vests over a period of four years. 25% of the shares are currently vested with the remaining 75% vesting annually on March 1, 2023, March 1, 2024 and March 1, 2025, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. The expiration date of this option reported in the table is the day before the tenth anniversary of the grant date of the option.
(3)  The option vests over a period of four years. 25% of the shares will vest on March 1, 2023, with the remaining 75% vesting annually thereafter on March 1, 2024, March 1, 2025 and March 1, 2026, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. The expiration date of this option reported in the table is the day before the tenth anniversary of the grant date of the option.
(4)  The shares underlying these restricted stock units vest on March 1, 2023, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.
(5)  Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
(6)  The shares underlying these restricted stock units vest over a period of two years, with one-half of the shares vesting on each of March 2, 2023 and March 2, 2024, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.
(7)  The shares underlying these restricted stock units vest over a period of two years, with one-half of the shares vesting on each of September 1, 2023 and September 1, 2024, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.
(8)  The shares underlying these restricted stock units vest over a period of three years, with one-third of the shares vesting on each of March 1, 2023, March 1, 2024 and March 1, 2025, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.
(9)  The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2023, subject to the Reporting Person's continuous service as an officer with the issuer as of the applicable vesting date.

Remarks:
Exhibit 24.1 - Power of Attorney

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Balthaser Kevin
C/O ACLARIS THERAPEUTICS, INC.
640 LEE ROAD, SUITE 200
WAYNE, PA 19087

Chief Financial Officer

Signatures
/s/ Mark Ballantyne, as Attorney-in-Fact 1/6/2023
**Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Feb 2023 to Mar 2023 Click Here for more Aclaris Therapeutics Charts.
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Mar 2022 to Mar 2023 Click Here for more Aclaris Therapeutics Charts.